Premium
5‐HT 1B Receptor Polymorphism and Clinical Response to Sumatriptan
Author(s) -
MaassenVanDenBrink Antoinette,
Vergouwe Monique N.,
Ophoff Roel A.,
Saxena Pramod R.,
Ferrari Michel D.,
Frants Rune R.
Publication year - 1998
Publication title -
headache: the journal of head and face pain
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.14
H-Index - 119
eISSN - 1526-4610
pISSN - 0017-8748
DOI - 10.1046/j.1526-4610.1998.3804288.x
Subject(s) - sumatriptan , migraine , agonist , medicine , allele , polymorphism (computer science) , receptor , pharmacology , anesthesia , gastroenterology , gene , biology , genetics
The 5‐HT 1 receptor agonist, sumatriptan, is highly effective in the treatment of migraine. Some patients, however, do not respond or experience recurrence of the headache. In addition, some patients report chest symptoms after sumatriptan. We investigated whether these different responses could be attributed to genetic diversity of the 5‐HT 1B receptor, which most likely mediates the therapeutic action and the coronary side effects of sumatriptan. Allele frequencies of two polymorphisms in the 5‐HT 1B receptor gene ( G861C and T‐261G ) were investigated in migraine patients with consistently good response to sumatriptan (n=14), with no response (n=12), with recurrence of the headache (n=12), with chest symptoms (n=13), and in patients without chest symptoms (n=27). Allele frequencies (G:0.74; C:0.26 at nt 861 and T:0.39; G:0.61 at nt ‐261) did not differ between patient groups, indicating that genetic diversity of the 5‐HT 1B receptor does not seem to be involved in the different clinical responses to sumatriptan.